Nature, Published online: 01 July 2026; doi:10.1038/s41586-026-10705-2 TROP2 marks poor-prognosis colorectal cancer cells with fetal-like, therapy-resistant states, and therapeutic targeting of TROP2 with antibody–drug conjugates in combination with chemotherapy enhances treatment efficacy by modulating tumour cell plasticity and overcoming resistance.
This research provides a breakthrough in understanding and targeting therapy-resistant colorectal cancer, happening as precision oncology and antibody-drug conjugates mature.
It identifies a key mechanism of therapy resistance in a common cancer, offering a new therapeutic strategy that could significantly improve patient outcomes.
The therapeutic landscape for colorectal cancer shifts towards TROP2-targeted therapies combined with chemotherapy, potentially overcoming current treatment limitations.
- · Oncology pharmaceutical companies
- · Colorectal cancer patients
- · Biotechnology sector
- · Antibody-drug conjugate developers
- · Traditional chemotherapy providers (if not adaptable)
- · Cancer research areas not focused on plasticity
Increased investment and clinical trials for TROP2-targeting agents in colorectal cancer and potentially other solid tumors.
Accelerated development of next-generation antibody-drug conjugates with enhanced tumor penetration and reduced systemic toxicity.
A broader paradigm shift in cancer treatment relying on understanding and manipulating tumor cell plasticity to prevent resistance.
This signal links to a primary source. Continuum Brief monitors and indexes it as part of the live intelligence stream — we do not republish source content.
Read at Nature — Latest Research